Study guide
4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms
ASCP Hematology Technologist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Hematopoiesis & Cellular Physiology
1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis
2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias
2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias
3 Chapter 3: Hemolytic Anemias & Erythrocytosis
3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification
4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation
4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment
5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms
5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies
6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems
6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia
7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation
7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays
8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics
8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis
9 Chapter 9: Laboratory Operations, Quality Assessment & Safety
9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges
4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms
Key Takeaways Explain This Topic AI
The diagnostic blast threshold for Acute Myeloid Leukemia is ≥20% in bone marrow or peripheral blood, but AML is definitively diagnosed regardless of blast count in the presence of t(8;21), inv(16)/t(16;16), or PML::RARA [t(15;17)].
Auer rods are fused primary azurophilic granules containing crystalline myeloperoxidase; their presence is pathognomonic for myeloid lineage differentiation and strictly excludes Acute Lymphoblastic Leukemia.
APL with PML::RARA [t(15;17)(q24.1;q21.2)] features hypergranular promyelocytes with faggot cells, carries an extreme risk of fatal consumptive coagulopathy/DIC, and responds to targeted differentiation therapy with ATRA and arsenic trioxide.
AML with RUNX1::RUNX1T1 [t(8;21)] exhibits large myeloblasts with salmon-pink granules and aberrant CD19 expression; AML with CBFB::MYH11 [inv(16)] shows abnormal bone marrow eosinophils with coarse purple-violet granules; both carry a favorable prognosis.
Cytochemical staining profiles distinguish lineages: MPO and Sudan Black B mark myeloblasts, Chloroacetate Esterase (Specific Esterase) marks granulocytic lineage, and Alpha-Naphthyl Acetate/Butyrate (Non-Specific Esterase) marks monocytic lineage with sodium fluoride inhibition.
Last updated: August 2026
Acute Myeloid Leukemia (AML) & Related Neoplasms
Acute Myeloid Leukemia (AML) is a clonal hematopoietic stem cell malignancy characterized by the uncontrolled proliferation and accumulation of poorly differentiated myeloid progenitor cells (blasts) in the bone marrow, peripheral blood, and other tissues. This malignant proliferation suppresses normal hematopoiesis, causing rapid-onset bone marrow failure manifested by severe anemia, neutropenia, and thrombocytopenia. ACUTE MYELOID LEUKEMIA (AML)
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- DIAGNOSTIC CRITERIA & MORPHOLOGY CYTOGENETICS & CYTOCHEMISTRY
- Blast threshold: ≥20% marrow/blood • Recurrent Genetic Abnormalities:
- (Exception: <20% if defining genetics) - APL with PML::RARA [t(15;17)]
- Myeloblast features: high N:C, delicate - AML with RUNX1::RUNX1T1 [t(8;21)]
- chromatin, 2–5 nucleoli, primary granules - AML with CBFB::MYH11 [inv(16)]
- Auer rods: Fused primary azurophilic - AML with KMT2A [11q23.3]
granules (MPO+); pathognomonic for • Cytochemical Staining Profile:
- myeloid lineage (NEVER in ALL) - MPO & Sudan Black B (+)
- Specific Esterase / CAE (+)
- Non-Specific Esterase / NSE (+ NaF-sensitive)
- 1. Diagnostic Criteria & Blast Thresholds (WHO 5th Edition & ICC 2022)
Under current World Health Organization (WHO 5th Edition) and International Consensus Classification (ICC 2022) frameworks, diagnosing Acute Myeloid Leukemia requires fulfilling defined quantitative blast thresholds or identifying disease-defining recurrent genetic abnormalities:
Standard Blast Threshold: The presence of ≥ 20 % \ge 20\% ≥ 20% blasts (myeloblasts, monoblasts, promonocytes, or megakaryoblasts) in the bone marrow nucleated differential or peripheral blood leukocyte count.
Genetically-Defined AML Exceptions (Diagnosed Regardless of Blast Count): When specific recurrent chromosomal translocations are identified, the diagnosis of AML is established even if the blast count is < 20 % <20\% < 20% :
AML with P M L : : R A R A PML::RARA PM L :: R A R A fusion [ t ( 15 ; 17 ) ( q 24.1 ; q 21.2 ) t(15;17)(q24.1;q21.2) t ( 15 ; 17 ) ( q 24.1 ; q 21.2 ) ]
AML with R U N X 1 : : R U N X 1 T 1 RUNX1::RUNX1T1 R U NX 1 :: R U NX 1 T 1 fusion [ t ( 8 ; 21 ) ( q 22 ; q 22.1 ) t(8;21)(q22;q22.1) t ( 8 ; 21 ) ( q 22 ; q 22.1 ) ]
AML with C B F B : : M Y H 11 CBFB::MYH11 CBFB :: M Y H 11 fusion [ inv ( 16 ) ( p 13.1 q 22 ) \text{inv}(16)(p13.1q22) inv ( 16 ) ( p 13.1 q 22 ) or t ( 16 ; 16 ) ( p 13.1 ; q 22 ) t(16;16)(p13.1;q22) t ( 16 ; 16 ) ( p 13.1 ; q 22 ) ]
Note on ICC Guidelines: ICC allows AML classification for other recurrent fusions (e.g., KMT2A , DEK::NUP214 ) with a blast threshold of ≥ 10 % \ge 10\% ≥ 10% .
2. Cytomorphology of Myeloblasts & Pathognomonic Auer Rods
Accurate identification of blast cytomorphology on Romanowsky / Wright-Giemsa stained marrow and peripheral blood films is the foundation of leukemia diagnosis: MYELOBLAST CYTOMORPHOLOGY
- ┌─────────────────────────────────────────────────────────┐
- │ Size: 15–20 µm (Moderate to Large) │
- │ Nucleus: Round, oval, or slightly indented │
- │ Chromatin: Fine, delicate, lacey, unaggregated │
- │ Nucleoli: 2 to 5 distinct, pale, prominent nucleoli │
- │ Cytoplasm: Moderate basophilic cytoplasm, agranular │
- │ or containing sparse azurophilic granules │
- │ Hallmarks: AUER RODS (Pathognomonic for Myeloid Lineage)│
- └─────────────────────────────────────────────────────────┘
- Auer Rods: Ultrastructure and Lineage Specificity
Biochemical Composition: Auer rods are elongated, needle-like, or cylindrical crystalline cytoplasmic inclusions formed by the abnormal aggregation and fusion of primary (azurophilic / lysosomal) granules . They contain concentrated crystalline myeloperoxidase (MPO) , lysosomal acid phosphatase, and chloroacetate esterase.
Diagnostic Pearl: Auer rods are pathognomonic for neoplasms of the myeloid lineage (AML, Myelodysplastic Syndromes with excess blasts). They are NEVER present in Acute Lymphoblastic Leukemia (ALL) or mature lymphoid malignancies.
- 3. AML with Recurrent Genetic Abnormalities RECURRENT GENETIC SUBTYPES OF AML
- │
- ┌─────────────────┬─────────┴─────────┬─────────────────┐
- ▼ ▼ ▼ ▼
- PML::RARA RUNX1::RUNX1T1 CBFB::MYH11 KMT2A (MLL)
- [t(15;17)] [t(8;21)] [inv(16)] [11q23.3]
- Hypergranular • Large Auer rods • Abnormal marrow • Monoblastic /
- promyelocytes • Salmon-pink eosinophils monocytic
- Faggot cells granules (purple-violet) • Tissue invasion
- Severe DIC risk • CD19 aberrant • Myelomonocytic (gingiva, skin)
- ATRA + ATO tx • Favorable • Favorable • Poor prognosis
1. Acute Promyelocytic Leukemia (APL) with P M L : : R A R A PML::RARA PM L :: R A R A [ t ( 15 ; 17 ) ( q 24.1 ; q 21.2 ) t(15;17)(q24.1;q21.2) t ( 15 ; 17 ) ( q 24.1 ; q 21.2 ) ]
Molecular Genetics: Reciprocal translocation fusing the Promyelocytic Leukemia gene ( PML ) on chromosome 15q24.1 with the Retinoic Acid Receptor Alpha gene ( RARA ) on chromosome 17q21.2. The resulting PML-RARA chimeric protein acts as a dominant-negative transcriptional repressor, binding nuclear corepressor complexes (HDACs) to block physiological promyelocyte differentiation.
Cytomorphology:
Classic Hypergranular APL: Markedly abnormal promyelocytes with reniform, bilobed, or butterfly-shaped nuclei and cytoplasm packed with heavy, coarse azurophilic granules. Characterized by pathognomonic "faggot cells" containing dense bundles, sheaves, or clusters of multiple Auer rods crisscrossing the cytoplasm.
Microgranular (Hypogranular) Variant: Blasts exhibit deeply folded, convoluted, cerebriform, or bilobed nuclei resembling monocytes with sparse, submicroscopic granules. Characterized by high leukocyte counts ( > 50 − 100 × 10 9 /L >50 - 100 \times 10^9\text{/L} > 50 − 100 × 1 0 9 /L ) and rapid kinetics.
Medical Emergency & Consumptive Coagulopathy: APL is the most urgent hematologic emergency due to life-threatening Disseminated Intravascular Coagulation (DIC) and hyperfibrinolysis. Abnormal promyelocytes express high levels of tissue factor (TF) , cancer procoagulant, and annexin II (a cell-surface receptor for plasminogen and tPA), precipitating massive thrombin generation, fibrinogen consumption, elevated D-dimer, and fatal intracranial or pulmonary hemorrhage.
Targeted Therapy: Immediate administration of All-Trans Retinoic Acid (ATRA / Tretinoin) in combination with Arsenic Trioxide (ATO) induces conformational changes, degrades the PML-RARA oncoprotein, and triggers terminal differentiation of malignant promyelocytes into mature neutrophils, curing > 90 % >90\% > 90% of patients without traditional cytotoxic chemotherapy.
2. AML with R U N X 1 : : R U N X 1 T 1 RUNX1::RUNX1T1 R U NX 1 :: R U NX 1 T 1 [ t ( 8 ; 21 ) ( q 22 ; q 22.1 ) t(8;21)(q22;q22.1) t ( 8 ; 21 ) ( q 22 ; q 22.1 ) ]
Molecular Genetics: Translocation fusing the RUNX1 (AML1) gene on 21q22 with the RUNX1T1 (ETO) gene on 8q22.1, generating a chimeric transcriptional repressor that halts myeloid differentiation.
Morphology: Large myeloblasts with abundant basophilic cytoplasm, prominent perinuclear hofs, large single Auer rods with tapered ends, and distinctive salmon-pink / pseudo-Chediak cytoplasmic granules . Often demonstrates dysplastic maturing neutrophils with abnormal nuclear lobulation.
Immunophenotypic Signature: Expresses pan-myeloid markers (CD13, CD33, CD34, CD117, MPO) with characteristic aberrant co-expression of B-cell lineage markers: CD19 and PAX5 , alongside CD56.
Prognosis: Highly favorable prognosis with high complete remission rates when treated with high-dose cytarabine consolidation.
3. AML with C B F B : : M Y H 11 CBFB::MYH11 CBFB :: M Y H 11 [ inv ( 16 ) ( p 13.1 q 22 ) \text{inv}(16)(p13.1q22) inv ( 16 ) ( p 13.1 q 22 ) or t ( 16 ; 16 ) ( p 13.1 ; q 22 ) t(16;16)(p13.1;q22) t ( 16 ; 16 ) ( p 13.1 ; q 22 ) ]
Molecular Genetics: Pericentric inversion of chromosome 16 or translocation fusing the Core-Binding Factor Beta gene ( CBFB ) at 16q22 with the smooth muscle Myosin Heavy Chain 11 gene ( MYH11 ) at 16p13.1.
Morphology: Acute myelomonocytic leukemia with bone marrow eosinophilia (formerly FAB M4Eo). Characterized by a dual proliferation of myeloblasts and monoblasts accompanied by abnormal bone marrow eosinophils containing large, coarse, purple-violet / basophilic immature granules mixed with normal specific eosinophilic granules.
Prognosis: Highly favorable prognosis ; belongs to the core-binding factor (CBF) leukemia family alongside t ( 8 ; 21 ) t(8;21) t ( 8 ; 21 ) .
4. AML with K M T 2 A KMT2A K MT 2 A ( M L L MLL M LL ) Rearrangement [11q23.3]
Molecular Genetics: Translocations involving the KMT2A (Lysine Methyltransferase 2A / Mixed Lineage Leukemia / MLL ) gene on chromosome 11q23.3, partnering with over 80 different partner genes (most commonly t ( 9 ; 11 ) ( p 22 ; q 23.3 ) t(9;11)(p22;q23.3) t ( 9 ; 11 ) ( p 22 ; q 23.3 ) partnering with MLLT3 ).
Morphology & Lineage: Predominantly monoblastic or monocytic leukemia (FAB M5a/M5b). Blasts show abundant cytoplasm with pseudopodia, delicate folded/convoluted nuclei, fine lacey chromatin, and intense non-specific esterase positivity.
Clinical Hallmarks: High propensity for extramedullary tissue infiltration , including marked gingival hypertrophy , cutaneous leukemia cutis (violaceous skin nodules), hepatosplenomegaly, and central nervous system (CNS) infiltration. Carries an intermediate to poor prognosis (except t ( 9 ; 11 ) t(9;11) t ( 9 ; 11 ) which has intermediate risk).
4. Cytochemical Staining in AML Differentiation
Cytochemical stains detect specific cellular enzymes or biochemical constituents within blast cytoplasm, providing definitive lineage assignment prior to or complementing flow cytometry: CYTOCHEMICAL STAINING MATRIX
- │
- ┌──────────────────────────┼──────────────────────────┐
- ▼ ▼ ▼
- MYELOPEROXIDASE (MPO) SPECIFIC ESTERASE (CAE) NON-SPECIFIC ESTERASE (NSE)
- Primary azurophilic • Naphthol AS-D • Alpha-naphthyl acetate/butyrate
- granules chloroacetate substrate
- Granulocytic lineage • Granulocytic lineage • Monocytic lineage (Monoblasts)
- Brown-black precipitate • Bright red/blue color • INHIBITED by Sodium Fluoride (NaF)
- SBB stains identically • Negative in monocytes • Dual esterase: Differentiates M4
- 1. Myeloperoxidase (MPO)
Biochemical Principle: Myeloperoxidase is a lysosomal heme enzyme located in primary (azurophilic) granules of granulocytes and lysosomes of monocytes. In the presence of hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 O 2 ), MPO oxidizes a benzidine-derived chromogen (e.g., 3,3'-diaminobenzidine / DAB) to form an insoluble, stable brown-to-black granular deposit.
Lineage Specificity: Strongly positive in myeloblasts, promyelocytes, and maturing granulocytes. Monocytes show weak, finely dispersed positivity. Lymphoblasts, erythroblasts, and megakaryoblasts are strictly MPO-negative .
Diagnostic Criterion: Demonstration of ≥ 3 % \ge 3\% ≥ 3% MPO-positive blasts definitively establishes myeloid lineage.
2. Sudan Black B (SBB)
Principle: A lipophilic dye that partitions into intracellular lipids, phospholipids, sterols, and neutral fats contained within primary and secondary granulocytic granules.
Diagnostic Utility: Stains parallel to MPO. SBB is particularly valuable because it can stain older or stored specimens where enzymatic MPO activity has degraded, and it is less sensitive to fixative inactivation.
3. Specific Esterase (SE / Chloroacetate Esterase / CAE)
Principle: Uses naphthol AS-D chloroacetate as a substrate. The cellular enzyme hydrolyzes the ester bond, liberating free naphthol compounds that couple with a diazonium salt to produce a bright red or blue insoluble precipitate.
Lineage Specificity: Marker of the granulocytic (neutrophilic) lineage (present from myeloblasts through mature segmented neutrophils). Mast cells are also strongly positive. Strictly negative in monocytic and lymphoid lineages.
4. Non-Specific Esterase (NSE / α \alpha α -Naphthyl Acetate or Butyrate)
Principle: Uses α \alpha α -naphthyl acetate or α \alpha α -naphthyl butyrate as substrate to identify non-specific carboxylic esterases distributed diffusely throughout the cytoplasm.
Lineage Specificity: Strongly, diffusely positive in monoblasts, promonocytes, monocytes, and macrophages . Granulocytic precursors are negative or show only weak, focal staining.
Sodium Fluoride (NaF) Inhibition Test: When sodium fluoride is added to the incubation medium, monocytic NSE activity is completely inhibited (inactivated) , abolishing the stain. In contrast, the weak focal NSE activity seen in granulocytes, megakaryocytes, or focal dot T-lymphocytes is fluoride-resistant . NaF sensitivity is the definitive proof of monocytic differentiation.
5. Dual Esterase Staining (CAE + NSE Combined)
Dual esterase staining combines Specific Esterase (CAE) and Non-Specific Esterase (NSE) on a single peripheral blood or bone marrow slide using contrasting chromogens (e.g., blue for CAE and reddish-brown for NSE). This allows simultaneous, distinct visualization and enumeration of granulocytic and monocytic blast populations in Acute Myelomonocytic Leukemia (AML-M4) .
Cytochemical Stain Target Component / Principle Granulocytic Series (Myeloblasts) Monocytic Series (Monoblasts) Lymphoid Series (Lymphoblasts) Erythroid / Megakaryocytic
Myeloperoxidase (MPO) Lysosomal enzyme in primary granules Strongly Positive ( ≥ 3 % \ge 3\% ≥ 3% ) Weak / Diffuse Strictly Negative Negative
Sudan Black B (SBB) Lipids and sterols in granules Strongly Positive Weak / Diffuse Strictly Negative Negative
Specific Esterase (CAE) Granulocytic chloroacetate esterase Positive (Bright Red/Blue) Negative Negative Negative
Non-Specific Esterase (NSE) α \alpha α -Naphthyl acetate/butyrate Negative or trace Intensely Positive Negative (T-cells: focal dot) Focal positive in megakaryocytes
NSE + Sodium Fluoride (NaF) Fluoride inhibition of monocytic enzyme Unchanged (Resistant) Inhibited / Negative Unchanged Unchanged
Periodic Acid-Schiff (PAS) Intracellular glycogen and glycoproteins Diffuse pale pink / granular Diffuse fine granular Coarse "Chunky Block" Positive Chunky positive in AML-M6; peripheral in M7
Terminal Transferase (TdT) Template-independent DNA polymerase Negative ( < 5 % <5\% < 5% ) Negative Intensely Positive ( > 95 % >95\% > 95% ) Negative